EditForce Entered into a License Agreement with Mitsubishi Tanabe Pharma to Develop and Commercialize Gene Therapies for Central Nervous System
- EditForce to receive ~$147.3M up front and milestones upon the development stage and commercialization progress along with royalties
- Under the terms of collaboration, MTPC to get an exclusive right to conduct the selection of drug candidate molecules, preclinical, clinical development, manufacturing, and commercialization globally
- The companies focus on research, developing, and commercializing gene therapy products for the specific CNS disease by using EditForce's PPR protein platform technology along with drug R&D and global business experience of MTPC
Ref: PRNewswire | Image: Mitsubishi Tanabe
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.